IL179512A0 - Methods of using il-1 antagonists to treat autoinflammatory disease - Google Patents

Methods of using il-1 antagonists to treat autoinflammatory disease

Info

Publication number
IL179512A0
IL179512A0 IL179512A IL17951206A IL179512A0 IL 179512 A0 IL179512 A0 IL 179512A0 IL 179512 A IL179512 A IL 179512A IL 17951206 A IL17951206 A IL 17951206A IL 179512 A0 IL179512 A0 IL 179512A0
Authority
IL
Israel
Prior art keywords
antagonists
methods
autoinflammatory disease
treat
treat autoinflammatory
Prior art date
Application number
IL179512A
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL179512A0 publication Critical patent/IL179512A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL179512A 2004-06-04 2006-11-23 Methods of using il-1 antagonists to treat autoinflammatory disease IL179512A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57702304P 2004-06-04 2004-06-04
PCT/US2005/019674 WO2005117945A1 (en) 2004-06-04 2005-06-03 Methods of using il-1 antagonists to treat autoinflammatory disease

Publications (1)

Publication Number Publication Date
IL179512A0 true IL179512A0 (en) 2007-05-15

Family

ID=34972252

Family Applications (1)

Application Number Title Priority Date Filing Date
IL179512A IL179512A0 (en) 2004-06-04 2006-11-23 Methods of using il-1 antagonists to treat autoinflammatory disease

Country Status (9)

Country Link
US (4) US7459426B2 (cg-RX-API-DMAC7.html)
EP (1) EP1750746A1 (cg-RX-API-DMAC7.html)
JP (2) JP5022216B2 (cg-RX-API-DMAC7.html)
CN (1) CN1964737B (cg-RX-API-DMAC7.html)
AU (1) AU2005249570B2 (cg-RX-API-DMAC7.html)
CA (1) CA2568352C (cg-RX-API-DMAC7.html)
IL (1) IL179512A0 (cg-RX-API-DMAC7.html)
MX (2) MXPA06014126A (cg-RX-API-DMAC7.html)
WO (1) WO2005117945A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005249503B2 (en) * 2003-11-10 2011-08-25 Vertex Pharmaceuticals Incorporated ICE inhibitors for the treatment of autoinflammatory diseases
ES2523147T3 (es) * 2004-02-26 2014-11-21 Baylor Research Institute Composiciones y métodos para el tratamiento sistémico de la artritis
WO2006076673A2 (en) * 2005-01-14 2006-07-20 Regeneron Pharmaceuticals, Inc. Use of il-i antagonists to treat polymyalgia rheumatica and giant cell arteritis
WO2007050607A2 (en) * 2005-10-26 2007-05-03 Novartis Ag Novel use of il-1beta compounds
CN101378764A (zh) * 2005-12-09 2009-03-04 贝勒研究院 通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测
EP2124997B1 (en) * 2006-10-20 2012-08-08 Regeneron Pharmaceuticals, Inc. Use of il-1 antagonists to treat gout and pseudogout
US7632490B2 (en) 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
JP5272735B2 (ja) * 2007-01-30 2013-08-28 国立大学法人 新潟大学 生物学的製剤
US20080227709A1 (en) * 2007-03-14 2008-09-18 Baylor Research Institute Gene expression in peripheral blood mononuclear cells from children with diabetes
KR102606597B1 (ko) 2007-05-29 2023-11-29 노파르티스 아게 항-ｉｌ-1-베타 치료법에 대한 신규 적응증
BR112012007137A2 (pt) 2009-09-30 2015-09-15 Harvard College metodos para modulacao da autofagia por meio da modulacao de produtos genicos inibidores da autofagia
PT2582391T (pt) 2010-06-18 2019-01-11 Xbiotech Inc Tratamento da artrite
CA2806438C (en) 2010-07-29 2021-04-13 Eleven Biotherapeutics, Inc. Chimeric il-1 receptor type i agonists and antagonists
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
HRP20191494T1 (hr) * 2012-03-31 2019-11-29 R Pharm Int Llc Pripravak derivat osteoprotegerina i njegova uporaba
CN103509100B (zh) * 2012-06-15 2017-10-27 上海百迈博制药有限公司 一种白细胞介素‑1受体拮抗剂突变体
WO2014035361A1 (en) * 2012-08-26 2014-03-06 R-PHARM, CJSC (Closed Joint Stock Company) IL-1β INHIBITOR COMPOSITION AND USE THEREOF
KR102236926B1 (ko) 2013-03-13 2021-04-06 세센 바이오, 아이엔씨. 안구 운반을 위한 키메릭 사이토카인 제제
JP2016520615A (ja) * 2013-05-31 2016-07-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法
HK1225742A1 (zh) * 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
WO2015147789A1 (en) * 2014-03-24 2015-10-01 R-Pharm Overseas, Inc. Human il 1-r1 derived inhibitor of il-1b
JP6565099B2 (ja) * 2015-09-18 2019-08-28 国立大学法人 長崎大学 家族性地中海熱のバイオマーカー
RU2022102624A (ru) * 2015-10-01 2022-03-10 Хит Байолоджикс, Инк. Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков
KR20180134880A (ko) * 2016-03-09 2018-12-19 슈 생-쥐스땡 주산기 이환율 및/또는 사망률을 감소시키는 방법
EP3582813A4 (en) * 2017-02-16 2020-12-30 XBiotech, Inc TREATMENT OF SUPPURATIVE HIDRADENITIS
BR112019020373A2 (pt) * 2017-04-03 2020-04-28 Wisconsin Alumni Research Foundation micropartículas revestidas com minerais para liberação sustentada de moléculas biologicamente ativas
JP2022524178A (ja) * 2019-01-07 2022-04-28 セルリス パルティシパソエス リミターダ タンデム受容体ｃａｒにおける二重特異性と腫瘍マイクロ環境を変調する方法
WO2021089782A1 (en) * 2019-11-07 2021-05-14 Inflazome Limited Treatment of autoinflammatory disorders
JP7072260B2 (ja) * 2019-12-27 2022-05-20 国立大学法人愛媛大学 マックル・ウェルズ症候群の治療用医薬組成物
WO2021184128A1 (en) * 2020-03-20 2021-09-23 Institut De Cardiologie De Montreal Methods of treating a coronavirus infection using colchicine
US20230210792A1 (en) * 2020-06-05 2023-07-06 Aristea Therapeutics, Inc. Use of a combination of colchicine and a cxcr-2 inhibitors for the treatment or prevention of familial mediterranean fever (fmf) and flare-ups thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
AU2001259758A1 (en) * 2000-05-12 2001-11-26 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
NZ538569A (en) * 2002-09-06 2009-02-28 Amgen Inc Therapeutic human anti-IL-1R1 monoclonal antibody
US20050129685A1 (en) * 2003-09-18 2005-06-16 Jingtai Cao Use of IL-1 blockers to prevent corneal inflammation and neovascularization

Also Published As

Publication number Publication date
JP2012111768A (ja) 2012-06-14
US7459426B2 (en) 2008-12-02
CN1964737B (zh) 2011-04-20
WO2005117945A1 (en) 2005-12-15
MX344967B (es) 2017-01-12
CA2568352A1 (en) 2005-12-15
EP1750746A1 (en) 2007-02-14
US8414876B2 (en) 2013-04-09
HK1100837A1 (en) 2007-09-28
MXPA06014126A (es) 2007-07-18
US20050272655A1 (en) 2005-12-08
JP2008501716A (ja) 2008-01-24
US20090156492A1 (en) 2009-06-18
US20110318342A1 (en) 2011-12-29
CN1964737A (zh) 2007-05-16
AU2005249570B2 (en) 2011-06-16
AU2005249570A1 (en) 2005-12-15
US20110311537A1 (en) 2011-12-22
CA2568352C (en) 2011-09-13
JP5022216B2 (ja) 2012-09-12

Similar Documents

Publication Publication Date Title
IL179512A0 (en) Methods of using il-1 antagonists to treat autoinflammatory disease
IS8371A (is) Notkun breyttra sýklósporína til að meðhöndla HCVsjúkdóma
LTC1761540I2 (lt) Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės-delta inhibitoriai
IL184371A0 (en) Methods of treating skin disorders using an il-31ra antagonist
IS8023A (is) Samsett meðferð til að meðhöndla ónæmisbólgusjúkdóma
DK1706112T3 (da) Fremgangsmåder til at behandle en inflammatorisk-beslægtet sygdom
ZA200802501B (en) Indenoisoquinolinone analogs and methods of use thereof
EP1827391A4 (en) DOSAGE FORMS AND METHODS OF USE THEREOF
IL176960A0 (en) Compositions and methods of treatment for inflammatory diseases
DK1948177T3 (da) Anvendelse af flibanserin til behandling af præmenopausale seksuelle lystforstyrrelser
IL177849A0 (en) Methods and compositions for treatment of autoimmune diseases
EP1874731A4 (en) CHINOBENZOXAZINANALOGA AND METHOD FOR THE APPLICATION
AP2715A (en) Use of imatinib to treat liver disorders and viralinfections
PL378210A1 (pl) Zastosowanie steroidów do leczenia osób cierpiących z powodu zaburzeń gałki ocznej
EP1613318A4 (en) COMPOUNDS AND ITS USE FOR THE TREATMENT OF DIABETES AND RELATED DISEASES
GB0404209D0 (en) Materials and methods for treatment of allergic disease
EP1765331A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY DISEASES
EP1740541A4 (en) THERAPEUTIC FORMULATIONS OF DESOXYEPOTHILONES
EP1755635A4 (en) TREATMENT OF INFLAMMATORY RESPIRATORY DISEASE
IL178970A0 (en) Haplotype markers and methods of using the same to determine response to treatment
GB0625235D0 (en) Treatment of hydrocarbons
DE602004011679D1 (de) Behandelung von Störungen
GB0526394D0 (en) Treatment of inflammatory diseases
SI2301576T1 (sl) Terapevtska uporaba protiteles proti CS1
GB0418762D0 (en) Methods and compositions to treat glaucoma